Reference
MHRA. Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects. Drug Safety Update 14: 9-10, No. 3, Oct 2020. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/928774/Oct-2020-DSU-PDF.pdf
Rights and permissions
About this article
Cite this article
Dolutegravir: risk of neural tube defects lower than thought. Reactions Weekly 1829, 2 (2020). https://doi.org/10.1007/s40278-020-85592-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-85592-0